Skip to main content
Antimicrobial Resistance and Infection Control logoLink to Antimicrobial Resistance and Infection Control
. 2018 Jan 22;7:13. doi: 10.1186/s13756-018-0304-6

The efficacy of ampicillin compared with ceftriaxone on preventing cesarean surgical site infections: an observational prospective cohort study

Srisuda Assawapalanggool 1, Nongyao Kasatpibal 2,, Supatra Sirichotiyakul 3, Rajin Arora 4, Watcharin Suntornlimsiri 5, Anucha Apisarnthanarak 6
PMCID: PMC5778626  PMID: 29387347

Abstract

Background

Cesarean surgical site infections (SSIs) can be prevented by proper preoperative antibiotic prophylaxis. Differences in antibiotic selection in clinical practice exist according to obstetricians’ preferences despite clear guidelines on preoperative antibiotic prophylaxis. This study aimed to compare the efficacy of ampicillin and ceftriaxone in preventing cesarean SSIs.

Methods

The observational prospective cohort study was conducted at a tertiary hospital in Thailand from 1 January 2007 to 31 December 2012. Propensity scores for ceftriaxone prophylaxis were calculated from potential influencing confounders. The cesarean SSI rates of the ceftriaxone group vs. those of the ampicillin prophylactic group were estimated by multilevel mixed-effects Poisson regression nested by propensity score.

Results

Data of 4149 cesarean patients were collected. Among these, 911 patients received ceftriaxone whereas 3238 patients received ampicillin as preoperative antibiotic prophylaxis. The incidence of incisional SSIs was (0.1% vs. 1.2%; p = 0.001) and organ space SSIs was (1.2% vs. 2.9%; p = 0.003) in the ceftriaxone group compared with the ampicillin group. After adjusting for confounders, the rate ratios of incisional and organ/space SSIs in the ceftriaxone compared with the ampicillin group did not differ (RR, 0.23; 95% CI 0.03–1.78), and (RR, 1.62; 95% CI 0.83–3.18), respectively.

Conclusion

These data indicate no difference exists between ampicillin and ceftriaxone to prevent SSIs after cesarean section. Ampicillin may be used as antibiotic prophylaxis in cesarean section.

Electronic supplementary material

The online version of this article (10.1186/s13756-018-0304-6) contains supplementary material, which is available to authorized users.

Keywords: ampicillin, ceftriaxone, propensity score, observational study, cesarean infections

Background

Cesarean section is an operation that has been increasingly performed in the USA [1] and also in the Asian region [2]. Surgical site infections (SSIs) occurring after this operation were estimated at 1.5 to 3.8% in the USA [3] and 0.9% in Thailand [4]. Proper surgical antibiotic prophylaxis is part of the SSI prevention bundles that have been recommended to surgical patients [5] including all cesarean patients [6, 7] to reduce the rate of post-cesarean SSIs [8]. It should be administered within 60 min before incision to ensure adequate concentration in the blood and tissue throughout the operation [7, 9].

Intraoperative redosing is required whenever the elapsed time from the first dose of antibiotic prophylaxis and operative time is longer than two half-lives of the antibiotic [9] because the failure of redosing during a long operation increases the risk of SSIs [10]. Redosing during surgery is also needed in the case of massive perioperative blood loss [9]. Increasing dosage may be required for obese patients to achieve the optimal level in the tissues [11]. Currently, a single 1-g intravenous dose of cefazolin [12] or at a higher dose of 2-g [9] is recommended as the first-line preoperative antibiotic of choice for cesarean patients. In spite of clear guidelines on preoperative antibiotic prophylaxis, differences in clinical practices remain, depending on obstetricians’ preference. Ceftriaxone and ampicillin have been prescribed in our setting and some others in Thailand.

Only one randomized controlled trial has been conducted to directly compare the efficacy of ampicillin vs. ceftriaxone concerning cesarean SSIs prevention and it lacked statistical power [13]. We therefore, conducted this study to compare the efficacy of ampicillin and ceftriaxone in the real context of preventing cesarean SSIs.

Methods

Study design and setting

This observational prospective cohort study was conducted from January 2007 to December 2012 in a tertiary center located on the northwest Thai-Myanmar border, where an average of 800 cesarean cases are performed annually.

Patients

Data of women undergoing cesarean operations during the study period were collected from our local infection control database. All patients undergoing cesarean operations included in the study received either ampicillin or ceftriaxone as the preoperative antibiotic prophylaxis accordingly to surgeon’s preference. In our setting, both ampicillin and ceftriaxone were 2-g dosages. Both preoperative antibiotic prophylaxis regimens were administered at the time of cord-clamp or within 60 min before incision and were discontinued for no longer than 24-h postoperatively. In total, all patients received either 3 doses of ampicillin or 2 doses of ceftriaxone according to standing order protocol in this setting. Patients with chorioamnionitis, prolonged ruptured membranes > 18 h, cases that switched to other regimens during the perioperative period or received other regimens and cases with improper administration time (> 60 min before incision) were excluded from the study. All six obstetricians in our setting followed the Centers for Disease Control and Prevention (CDC) guidelines of SSI prevention [14] and also prescribed preoperative antibiotic prophylaxis for all patients undergoing cesarean operation during the study period.

Data collection

Demographic data, background medical problems, antenatal care history and referral data were collected. Perinatal and perioperative data, e.g., chief complaints, clinical findings on physical examination, progression of labor, transvaginal procedures before undergoing operation, surgeons, place of antenatal care, PROM, being referred from local settings, failure to induce labor, being preterm, having an emergency operation, being affected by acquired human immunodeficiency syndrome, multiple gestations, wound class and operative details, were also gathered. Patients in our center had not been screened for group B Streptococcus. Clinical outcomes and data from postdischarge surveillance system were provided 30-day follow-up and recorded. Wounds of all patients were checked on the third postoperative day, whenever necessary and on the day of discharge. One week and 30-day follow-up was appointed for every patient. Any patient with wound complications or gynecologic problems was referred for consultation at our center. Loss of attending any follow-up appointments in our network was classified as lost to follow-up. This observational study was approved by the Research Ethics Committee 4, Faculty of Medicine, Chiang Mai University (reference no. 186/2013).

Clinical response, clinical outcome and definitions

The outcome of this study was cesarean SSIs incidence of both antibiotic cohorts and was defined according to the National Healthcare Safety Network surveillance of CDC criteria [15]. Case surveillance was conducted by infection control nurses and personnel in the postdischarge surveillance system according to the surveillance criteria.

Statistical analysis

Continuous data were described and properly compared using student t-test or Wilcoxon rank-sum test depending on their distributions. Fisher’s exact test was used to compare discrete data.

Propensity scores for ceftriaxone prophylaxis were calculated from potential factors influencing or placing patients more likely in one preoperative antibiotic group than another. These included individual surgeons, private antenatal care, premature rupture of the membranes (ROM), being referred from local settings, failure to induce labor, being preterm, having an emergency operation, affected by acquired human immunodeficiency syndrome, multiple gestations and wound class ≥3.

The cesarean SSI rates of ceftriaxone vs. those of the ampicillin prophylactic group were estimated by multilevel mixed-effects Poisson regression and were expressed as rate ratio (RR). The potential confounding factors revealed from a related study [16] including ethnic minority, anemia, being referred, preterm, primigravida, pelvic examination ≥5 times before cesarean operation, foul-smelling amniotic fluid, wound class ≥3, operation time > 55 min, and emergency operation were all adjusted in the fixed-effects part of the model nested within propensity scores as random-effects part to fully control the effect of confounding bias and residual confounders because these factors could not be constructed homogenous subclass in propensity score [17]. We found some confounders by indication were also risk factors for cesarean SSIs in our setting [16] including being primigravida, preterm, being referred, wound class ≥3, emergency operation and multiple gestations. We therefore included these confounders in multivariable multilevel regression model because these potential confounding factors could distort the outcome. In addition, double-adjustment could reduce residual confounding biases [18, 19] and another reason was that all confounders should be fully controlled in the efficacy study [20]. We used Kaplan-Meier survival curves to compare survival of caesarean SSIs between the ceftriaxone and ampicillin groups. P-values were obtained from Cox’s survival regression analysis. We considered P-values of less than 0.05 as statistically significant. All data were analyzed using STATA®, version 11.2 (StataCorp).

Results

In total, 5122 patients underwent cesarean sections. Of these, 134 patients were lost to follow-up. Of the remaining patients, 24 received antibiotics other than ampicillin and ceftriaxone as preoperative prophylaxis, 345 patients received improper antibiotic-administration time and 470 patients presented ROM > 18 h accompanied by fever before the cohort zero-th time, and all were excluded from the study (Fig. 1). Thus, a total of 4149 patients were included in the study. Among these, 911 patients received ceftriaxone and 3238 patients received ampicillin as preoperative antibiotic prophylaxis. Baseline characteristics and propensity scores differed between the two comparison groups and the results are shown in Table 1.

Fig. 1.

Fig. 1

Data flow of the study

Table 1.

Characteristics of patients receiving antibiotic prophylaxis with ceftriaxone and ampicillin (n = 4149)

Characteristic Ceftriaxone (n = 911) Ampicillin (n = 3238) p-value
n % n %
Age (yr)
  < 20 24 2.6 209 6.5
 20–34 691 75.9 2391 73.8
  ≥ 35 196 21.5 638 19.7
 Mean ± SD 30.2 ±5.3 28.9 ±6.2 < 0.001
Ethnic minority 130 14.3 1788 55.2 < 0.001
Education level
 None 88 9.7 1513 46.7 < 0.001
 Primary 99 10.9 598 18.5
 Intermediate 236 25.9 673 20.8
 College/higher 488 53.5 454 14.0
Antenatal care
 No 3 0.3 72 2.2 < 0.001
 Camp 40 4.4 827 25.5
 Hospital 868 95.3 2339 72.3
Body weight (kg)
  ≥ 80 155 17.0 408 12.6
 Mean ± SD 69.0 ±11.7 65.4 ±12.4 < 0.001
Hb (g/dL)
  < 11 145 15.9 617 19.1
 Mean ± SD 11.5 ±1.0 11.4 ±1.2 0.008
HIV positive 5 0.6 124 3.8 < 0.001
Referral 48 5.3 1070 33.1 < 0.001
Gravida
Primigravida 308 33.8 1140 35.2
Median (IQR) 2 (1–2) 2 (1–3) 0.002
Multiple gestations 13 1.4 123 3.8 < 0.001
GA (weeks)
  < 37 26 2.9 425 13.1
 Mean ± SD 38.6 ±1.3 38.4 ±2.4 0.152
PV ≥5 occasions before surgery 17 1.9 405 12.5 < 0.001
Amniotic fluid
 Clear 896 98.4 2757 85.2 < 0.001
 MSAF 11 1.2 468 14.4
 Foul smelling 4 0.4 13 0.4
ROM duration (hr)
 Median (IQR) 0 (0–0) 0 (0–2.3) < 0.001
Fetal death 5 0.6 38 1.2 0.136
ASA score ≥ 3 19 2.1 198 6.1 < 0.001
Wound class ≥3 15 1.7 364 11.2 < 0.001
Operation time (min)
  ≥ 55 93 10.2 1209 37.3
 Median (IQR) 40 (35–45) 50 (40–60) < 0.001
Emergency 214 23.5 2487 76.8 < 0.001
EBL (mL)
  ≥ 500 121 13.3 1956 60.4
 Median (IQR) 300 (300–400) 500 (400–500) < 0.001
UTI 1 0.1 9 0.3 0.701
Skin incision line
 Midline 119 13.1 1492 46.1 < 0.001
 Pfannelstein 792 86.9 1746 53.9
Addition procedures
 Appendectomy/TR 542 59.5 1432 44.2 < 0.001
Propensity score
 Mean ± SD 0.86 ±0.27 0.04 ±0.11 < 0.001
 Median (IQR) 0.96 (0.92–0.96) 0.02 (0.01–0.03) < 0.001

ASA American Society of Anesthesiology, MSAF Meconium stained amniotic fluid, dL Decilitre, EBL Estimated blood loss, g Gram, GA Gestational age, Hb Hemoglobin, HIV Human immunodeficiency virus, hr. Hours, IQR Interquartile range, kg Kilogram, min Minute, PV Pelvic examinations, ROM Rupture of amniotic membranes, SD Standard deviation, SSIs Surgical site infections, TR Tubal resection, UTI Urinary tract infection, mL Millilitre, yr. Years

The incidence of incisional SSIs was 0.1% (1/911) vs. 1.2% (39/3238); P = 0.001 and organ space SSIs was 1.2% (11/911) vs. 2.9% (94/3238); P = 0.003 in the ceftriaxone group compared with the ampicillin group (Table 2). Among 145 patients, who developed cesarean SSIs, 46 cases (31.7%) were investigated for pathogens. Negative finding resulted in 26 cases, positive one isolation resulted in 15 cases and two isolations resulted in 5 cases. Resistant organisms to preoperative antibiotic comprised 14 isolates in the ampicillin group and one in the ceftriaxone group. The remaining 10 isolates were susceptible to ampicillin (Table 3).

Table 2.

Comparison of cesarean surgical site infections between patients receiving ceftriaxone vs. those receiving ampicillin

Characteristic Ceftriaxone (n = 911) Ampicillin (n = 3238) p-value
n % n %
Total Cesarean SSIs
 yes 12 1.3 133 4.1 < 0.001
  no 899 98.7 3105 95.9
Incisional SSIs
 yes 1 0.1 39 1.2 0.001
 no 910 99.9 3199 98.8
Organ/space SSIs
 yes 11 1.2 94 2.9 0.003
 no 900 98.8 3144 97.1

SSIs Surgical site infections

Table 3.

Pathogens isolated from 51 cesarean surgical site infections

Pathogen Number of isolates (n = 51) Percentage of isolates
No growth 26 50.9
Susceptible to antibiotic used
Klebsiella pneumoniae 4 7.8
Escherichia coli 3 5.8
Acinetobacter baumannii 2 3.9
Proteus mirabilis 1 2.0
Resistant to antibiotic used
Staphylococcus aureus 5 9.8
 Coagulase-negative Staphylococci 5 9.8
Enterococcus faecalis 1 2.0
Enterococcus faecium 1 2.0
Escherichia coli 1 2.0
Pseudomonas aeruginosa 1 2.0
Yeasts 1 2.0

After adjusting for propensity scores and other confounding factors included age, being referred, education level, body weight, being an ethnic minority, anemia, pelvic examination more than 4 before cesarean section, being preterm, wound class 3 or more, presence of foul-smelling amniotic fluid, longer than 55-min operative time, emergency operation, ASA-score of 3 or more, being primigravida, estimated blood loss, skin incision line and addition procedures; rate ratios with 95% confidence interval of total cesarean SSIs, incisional SSIs and organ/space SSIs in the ceftriaxone group compared with the ampicillin group were 1.10; 95% CI 0.58–2.08, 0.23; 95% CI 0.03–1.78 and 1.62; 95% CI 0.83–3.18, respectively (Table 4). The Kaplan-Meier survival curves of overall cesarean SSIs, incisional SSIs, and organ/space SSIs with p-values between the ceftriaxone and ampicillin groups are demonstrated in Figs. 2, 3 and 4. The Kaplan-Meier survival curves stratified by potential risk factors of cesarean SSIs are provided in the Additional file 1: Appendix.

Table 4.

Risk ratio of cesarean SSIs comparing ceftriaxone to ampicillin groups after multilevel mixed-effects Poisson regression

Outcome RR 95% Confidence interval p-value
Total cesarean SSIs 1.10 0.58–2.08 0.765
Cesarean incisional SSIs 0.23 0.03–1.78 0.158
Cesarean organ/space SSIs 1.62 0.83–3.18 0.160

RR Risk ratio, SSIs Surgical site infections

Fig. 2.

Fig. 2

Adjusted overall cesarean SSIs survival by type of antibiotic prophylaxis. P-value was obtained from Cox’s survival regression analysis. AMP ampicillin group, CTX ceftriaxone group, K-M Kaplan-Meier, SSIs surgical site infections

Fig. 3.

Fig. 3

Adjusted cesarean incisional SSIs survival by type of antibiotic prophylaxis. P-value was obtained from Cox’s survival regression analysis. AMP ampicillin group, CTX ceftriaxone group, K-M Kaplan-Meier, SSIs surgical site infections

Fig. 4.

Fig. 4

Adjusted cesarean organ/space SSIs survival by type of antibiotic prophylaxis. P-value was obtained from Cox’s survival regression analysis. AMP ampicillin group, CTX ceftriaxone group, K-M Kaplan-Meier, SSIs surgical site infections

Discussion

Our study revealed a comparable efficacy of ampicillin and ceftriaxone, newer generation and broader antibacterial spectra-antibiotics, in preventing cesarean SSIs. In the antibiotic-resistant microorganism era, this is useful for promoting rational antibiotic use programs to prescribe more specific and narrower antibacterial spectra. As a result, it can prevent emerging multidrug resistant organisms after selective pressure from broad spectrum antibiotics overuse [2124], a crisis that has been widely reported and tends to increase worldwide [25]. Ampicillin is also cheaper and may fit limited-resource settings.

The ideal study to compare the efficacy among antibiotic prophylaxis regimens is a randomized control design where all confounders are equally distributed on all comparison groups [26]. However, such a study design cannot be conducted in many circumstances in almost all routine clinical practices. In real practice, antibiotic prophylaxis is assigned for each patient based on beneficence and non-maleficence, under individual circumstances or indication and non-randomly. The observational study on assigned antibiotic prophylaxis to patients in the real context as in this study is optional and more feasible [27]. However, the confounders by indication among comparison groups in the observational study were inevitable [2830]. In our study, demographic data differed between the two comparison groups. Confounding biases from an imbalance of baseline demographic data, acting as prognostic factors, should be controlled by adjusting in the model of regression [28]. We used propensity score to estimate probability of prescribing ceftriaxone for cesarean SSIs prophylaxis from abovementioned confounders by indication.

Propensity score or balancing score in other words, represented a scalar quantity that is calculated from a set of confounders by indication and contra-indication. It represents the conditional probability of receiving a particular treatment in the context and is used to control the effect of such confounders by adjusting it in the model of multivariable regression [31, 32].

The estimators for comparing of antibiotic prophylaxis groups concerning cesarean SSIs prevention in this study became non-different after confounders and propensity score was adjusted in the regression model (Table 4) and met the same direction as related well-designed studies [13].

The half-life of antibiotics used for SSIs prophylaxis is another important issue of concern. Redosing of antibiotic prophylaxis is needed when operative time is longer than two half-lives of the antibiotic used to ensure that the tissue level of the antibiotic is above the minimum inhibitory concentration of common pathogens of SSIs for that operation [9]. The half-lives of ampicillin and ceftriaxone are 1.7 ± 0.3 h [33, 34] and 6.3–6.9 h [35], respectively. Compared with the 75th percentile cesarean operation time reported by the National Nosocomial Infections Surveillance (NNIS) and in Thailand, including our setting, it required less than 60 min [16, 36, 37]. Therefore, the redosing of ampicillin and ceftriaxone in this situation may not be required. Additionally however, either two doses of ampicillin or a single dose of ceftriaxone was given within the first 24 h after cesarean section in the study setting. The use of a single dose preoperative antibiotic prophylaxis for cesarean delivery is a major challenge in this setting. In addition, the choice of antibiotic prophylaxis should be selected in accordance with standard guidelines [9, 12].

The strength of this study was the large study size that was sufficient to detect differences among groups. Post-hoc power analyses have shown that the power of this study for overall cesarean SSIs, cesarean incisional and organ/space SSIs was estimated to be 99.78, 96.18, and 89.01%, respectively. In addition, our observational design comprised a mixed-population that could represent real-world circumstances, so the results could be more generalized or applied. The propensity score technique with multilevel analysis and advanced statistical methods was used in data analysis to estimate the efficacy of both regimens. The results from our study were comparable to one related meta-analysis of randomized controlled trials [32]. This may be useful for periodic monitoring of the efficacy without conducting an experimental study. However, some limitations were revealed in this study. Propensity scores can incorporate only known confounding by indicated factors. They cannot adjust the effect of the unknown confounders or covariates that have not been collected for analysis [32, 38, 39]. Another limitation is its generalizability because the study was conducted in a single setting and all patients received either 3 doses of ampicillin or 2 doses of ceftriaxone in accordance with standing order protocol. The findings from our study might not be generalizable to other settings that prescribed the differences in dose and choice of antibiotic prophylaxis; however, it could be applied to similar settings. Pooled data from other sites should be studied in advance.

Conclusions

The efficacy of ampicillin and ceftriaxone to prevent cesarean SSIs did not differ indicating that ampicillin may be used as an antibiotic prophylaxis in cesarean sections. Propensity scores can be used in data analysis of an observational study to compare the efficacy of antibiotic prophylaxis regimens and repeat performance as a monitoring measure.

Acknowledgements

The authors wish to thank Professor Dr. Jayanton Patumanond, Clinical Research Center, Faculty of Medicine, Thammasat University for statistical analysis assistance.

Funding

None.

Availability of data and materials

Data from this study are currently not publicly available. They will be made available to the interested researchers by the first author of this article whenever reasonable.

Abbreviations

ASA

American Society of Anesthesiology

CDC

Centers for Disease Control and Prevention

dL

Decilitre

EBL

Estimated blood loss

G

gram

GA

Gestational age

Hb

Hemoglobin

HIV

Human immunodeficiency virus

Hr

hours

IQR

Interquartile range

Kg

Kilogram

Min

Minute

mL

Millilitre

MSAF

Meconium stained amniotic fluid

NNIS

National Nosocomial Infections Surveillance

PV

Pelvic examinations

ROM

Rupture of the membranes

RR

Rate ratios

SD

Standard deviation

SSIs

Surgical site infections

SSIs

Surgical site infections

TR

tubal resection

UTI

Urinary tract infection

Yr

Years

Additional file

Additional file 1: (95.4KB, docx)

Appendix (DOCX 95 kb)

Authors’ contributions

SA, NK, SS, RA, WS and AA designed the study and reviewed the manuscript for important view. SA, NK analyzed the data and wrote the manuscript. AA took part in data analysis and critically reviewed the manuscript. Collecting and examining the data for their integrity and validity were the responsible of SA and NK. All the authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Research Ethics Committee 4, Faculty of Medicine, Chiang Mai University (reference no. 186/2013).

Consent for publication

Consent for publication is not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Footnotes

Electronic supplementary material

The online version of this article (10.1186/s13756-018-0304-6) contains supplementary material, which is available to authorized users.

Contributor Information

Srisuda Assawapalanggool, Email: srisopon1@gmail.com.

Nongyao Kasatpibal, Phone: +66918560700, Phone: +6653949017, Email: nongyaok2003@gmail.com.

Supatra Sirichotiyakul, Email: ssiricho@mail.med.cmu.ac.th, Email: supatra.s@cmu.ac.th.

Rajin Arora, Email: drrajin@gmail.com.

Watcharin Suntornlimsiri, Email: watcsoon@gmail.com.

Anucha Apisarnthanarak, Email: anapisarn@yahoo.com.

References

  • 1.Osterman MJ, Martin JA. Trends in low-risk cesarean delivery in the United States, 1990-2013. Natl Vital Stat Rep. 2014;63(6):1–16. [PubMed] [Google Scholar]
  • 2.Festin MR, Laopaiboon M, Pattanittum P, Ewens MR, Henderson-Smart DJ, Crowther CA. Caesarean section in four south east Asian countries: reasons for, rates, associated care practices and health outcomes. BMC Pregnancy Childbirth. 2009;9:17. doi: 10.1186/1471-2393-9-17. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Edwards JR, Peterson KD, Mu Y, Banerjee S, Allen-Bridson K, Morrell G, et al. National Healthcare Safety Network (NHSN) report: data summary for 2006 through 2008, issued December 2009. Am J Infect Control. 2009;37(10):783–805. doi: 10.1016/j.ajic.2009.10.001. [DOI] [PubMed] [Google Scholar]
  • 4.Kasatpibal N, Jamulitrat S, Chongsuvivatwong V. Standardized incidence rates of surgical site infection: a multicenter study in Thailand. Am J Infect Control. 2005;33(10):587–594. doi: 10.1016/j.ajic.2004.11.012. [DOI] [PubMed] [Google Scholar]
  • 5.Allegranzi B, Zayed B, Bischoff P, Kubilay NZ, de Jonge S, de Vries F, et al. New WHO recommendations on intraoperative and postoperative measures for surgical site infection prevention: an evidence-based global perspective. Lancet Infect Dis. 2016;16(12):e288-e303. [DOI] [PubMed]
  • 6.The American College of Obstetricians and Gynecologists. ACOG Committee Opinion No 465: antimicrobial prophylaxis for cesarean delivery: timing of administration. Obstet Gynecol. 2010;116(3):791–792. doi: 10.1097/AOG.0b013e3181f68086. [DOI] [PubMed] [Google Scholar]
  • 7.Berríos-Torres SI, Umscheid CA, Bratzler DW, et al. Centers for disease control and prevention guideline for the prevention of surgical site infection. JAMA Surg. 2017;152(8):784-91. [DOI] [PubMed]
  • 8.Smaill Fiona M, Grivell RM. Antibiotic prophylaxis versus no prophylaxis for preventing infection after cesarean section. Cochrane Database Syst Rev. 2014;10 [DOI] [PMC free article] [PubMed]
  • 9.Bratzler DW, Dellinger EP, Olsen KM, Perl TM, Auwaerter PG, Bolon MK, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195–283. doi: 10.2146/ajhp120568. [DOI] [PubMed] [Google Scholar]
  • 10.Kasatpibal N, Whitney JD, Dellinger EP, Nair BG, Pike KC. Failure to Redose antibiotic prophylaxis in long surgery increases risk of surgical site infection. Surg Infect. 2017;18(4):474–484. doi: 10.1089/sur.2016.164. [DOI] [PubMed] [Google Scholar]
  • 11.Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy. 2007;27(8):1081–1091. doi: 10.1592/phco.27.8.1081. [DOI] [PubMed] [Google Scholar]
  • 12.The American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No 120: use of prophylactic antibiotics in labor and delivery. Obstet Gynecol. 2011;117(6):1472–1483. doi: 10.1097/AOG.0b013e3182238c31. [DOI] [PubMed] [Google Scholar]
  • 13.Gyte GM, Dou L, Vazquez JC. Different classes of antibiotics given to women routinely for preventing infection at caesarean section. Cochrane Database Syst Rev. 2014;(11):1-191. [DOI] [PMC free article] [PubMed]
  • 14.Mangram AJ, Horan TC, Pearson ML, Silver LC, Jarvis WR. Guideline for prevention of surgical site infection, 1999. Hospital infection control practices advisory committee. Infect Control Hosp Epidemiol. 1999;20(4):250–278. doi: 10.1086/501620. [DOI] [PubMed] [Google Scholar]
  • 15.Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332. doi: 10.1016/j.ajic.2008.03.002. [DOI] [PubMed] [Google Scholar]
  • 16.Assawapalanggool S, Kasatpibal N, Sirichotiyakul S, Arora R, Suntornlimsiri W. Risk factors for cesarean surgical site infections at a Thai-Myanmar border hospital. Am J Infect Control. 2016;44(9):990–995. doi: 10.1016/j.ajic.2016.01.031. [DOI] [PubMed] [Google Scholar]
  • 17.Rubin DB, Thomas N. Combining propensity score matching with additional adjustments for prognostic covariates. J Amer Statistical Assoc. 2000;95(450):573–585. doi: 10.1080/01621459.2000.10474233. [DOI] [Google Scholar]
  • 18.Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46(3):399–424. doi: 10.1080/00273171.2011.568786. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Nguyen TL, Collins GS, Spence J, Daures JP, Devereaux PJ, Landais P, et al. Double-adjustment in propensity score matching analysis: choosing a threshold for considering residual imbalance. BMC Med Res Methodol. 2017;17(1):78. doi: 10.1186/s12874-017-0338-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Grobbee DE, Hoes AW. Clinical epidemiology: principles, methods, and applications for clinical research. 2. Massachusetts: Jones & Bartlett Learning; 2015. p. 472. [Google Scholar]
  • 21.Pouladfar G, Jafarpour Z, Hosseini SA, Janghorban P, Roozbeh J. Antibiotic selective pressure and development of bacterial resistance detected in bacteriuria following kidney transplantation. Transplant Proc. 2015;47(4):1131–1135. doi: 10.1016/j.transproceed.2014.11.062. [DOI] [PubMed] [Google Scholar]
  • 22.Alonso A, Campanario E, Martinez JL. Emergence of multidrug-resistant mutants is increased under antibiotic selective pressure in Pseudomonas Aeruginosa. Microbiology. 1999;145(Pt 10):2857–2862. doi: 10.1099/00221287-145-10-2857. [DOI] [PubMed] [Google Scholar]
  • 23.Kolar M, Urbanek K, Latal T. Antibiotic selective pressure and development of bacterial resistance. Int J Antimicrob Agents. 2001;17(5):357–363. doi: 10.1016/S0924-8579(01)00317-X. [DOI] [PubMed] [Google Scholar]
  • 24.Dinubile MJ, Friedland I, Chan CY, Motyl MR, Giezek H, Shivaprakash M, et al. Bowel colonization with resistant gram-negative bacilli after antimicrobial therapy of intra-abdominal infections: observations from two randomized comparative clinical trials of ertapenem therapy. Eur J Clin Microbiol Infect Dis. 2005;24(7):443–449. doi: 10.1007/s10096-005-1356-0. [DOI] [PubMed] [Google Scholar]
  • 25.World Health Organization . Antimicrobial resistance: global report on surveillance. France: World Health Organization; 2014. [Google Scholar]
  • 26.Sibbald B, Roland M. Understanding controlled trials. Why are randomised controlled trials important? BMJ. 1998;316(7126):201. doi: 10.1136/bmj.316.7126.201. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Fletcher RH, Fletcher SW. Treatment. In: Fletcher RH, Fletcher SW, editors. Clinical epidemiology: the essentials. 4. Philadelphia: Lippincott Williams & Wilkins; 2005. pp. 125–145. [Google Scholar]
  • 28.Kramer MS. Analytic bias. In: Kramer MS, editor. Clinical epidemiology and biostatistics. 1. Berlin: Springer-Verlag; 1988. pp. 47–57. [Google Scholar]
  • 29.Hullsiek KH, Louis TA. Propensity score modeling strategies for the causal analysis of observational data. Biostatistics. 2002;3(2):179–193. doi: 10.1093/biostatistics/3.2.179. [DOI] [PubMed] [Google Scholar]
  • 30.Miettinen OS. The need for randomization in the study of intended effects. Stat Med. 1983;2(2):267–271. doi: 10.1002/sim.4780020222. [DOI] [PubMed] [Google Scholar]
  • 31.D’Agostino RB., Jr Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med. 1998;17(19):2265–2281. doi: 10.1002/(SICI)1097-0258(19981015)17:19&#x0003c;2265::AID-SIM918&#x0003e;3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  • 32.Austin PC. The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments. Stat Med. 2014;33(7):1242–1258. doi: 10.1002/sim.5984. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Sjovall J, Alvan G, Huitfeldt B. Intra- and inter-individual variation in pharmacokinetics of intravenously infused amoxycillin and ampicillin to elderly volunteers. Br J Clin Pharmacol. 1986;21(2):171–181. doi: 10.1111/j.1365-2125.1986.tb05172.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Ehrnebo M, Nilsson SO, Boreus LO. Pharmacokinetics of ampicillin and its prodrugs bacampicillin and pivampicillin in man. J Pharmacokinet Biopharm. 1979;7(5):429–451. doi: 10.1007/BF01062386. [DOI] [PubMed] [Google Scholar]
  • 35.Yuk JH, Nightingale CH, Quintiliani R. Clinical pharmacokinetics of ceftriaxone. Clin Pharmacokinet. 1989;17(4):223–235. doi: 10.2165/00003088-198917040-00002. [DOI] [PubMed] [Google Scholar]
  • 36.Kasatpibal N, Norgaard M, Jamulitrat S. Improving surveillance system and surgical site infection rates through a network: a pilot study from Thailand. Clin Epidemiol. 2009;1:67–74. doi: 10.2147/CLEP.S5507. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Centers for Disease Control and Prevention National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32(8):470–485. doi: 10.1016/j.ajic.2004.10.001. [DOI] [PubMed] [Google Scholar]
  • 38.Shah BR, Laupacis A, Hux JE, Austin PC. Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review. J Clin Epidemiol. 2005;58(6):550–559. doi: 10.1016/j.jclinepi.2004.10.016. [DOI] [PubMed] [Google Scholar]
  • 39.Trojano M, Pellegrini F, Paolicelli D, Fuiani A, Di Renzo V. Observational studies: propensity score analysis of non-randomized data. Int MS J. 2009;16(3):90–97. [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Data from this study are currently not publicly available. They will be made available to the interested researchers by the first author of this article whenever reasonable.


Articles from Antimicrobial Resistance and Infection Control are provided here courtesy of BMC

RESOURCES